Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib - Waldschmidt, D; Merle, P; Granito, A; Huang, YH; Bodoky, G; Yokosuka, O; Rosmorduc, O; Breder, VV; Gerolami, R; Masi, G; Ross, PJ; Quinn, S; Song, T; Bronowicki, JP; Ollivier-Hourmand, I; Kudo, M; Xu, L; Baumhauer, A; Meinhardt, G; Han, G; Bruix, J (Zeitschrift für Gastroenterologie, 2018)